HanAll Biopharma Co., Ltd.
http://www.hanallbiopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From HanAll Biopharma Co., Ltd.
OKYO Hits Multiple Dry Eye Endpoints, Plans Move Into Phase III
OKYO’s eye drop OK-101 has hit endpoints for ocular pain, tear film breakup time and conjunctival staining in Phase II, while demonstrating a placebo-like tolerability profile.
Sylentis Piles On Another Failure In Dry Eye
The PharmaMar subsidiary is the latest group to crash in a notoriously hard-to-treat disease, leaving Bausch + Lomb more firmly in command of the field.
'Know The Enemy And Know Yourself' Before Entering US, Daewoong Exec Advises
Daewoong Innovation Holdings President Thierry Uh tells Scrip what Korean pharma firms should keep in mind when entering the US market, as well as what R&D and partnering strategies Daewoong has both there and globally.
Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's
Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice